SCHEMBL3484572

SCHEMBL3484572

Nc1ccc(Oc2cccc3ccccc23)c(Cl)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESRRA P11474 2/20 0.56
SCN9A Q15858 2/20 0.48
ITGB2 P05107 1/20 0.47
ICAM1 P05362 1/20 0.47
ITGAL P20701 1/20 0.47
KDM1A O60341 1/20 0.45
RCOR1 Q9UKL0 1/20 0.45
HPGD P15428 1/20 0.44
RHEB Q15382 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP2A6 P11509 1/20 0.41
STK39 Q9UEW8 3/20 0.40
HTR1B P28222 2/20 0.40
SIRT2 Q8IXJ6 1/20 0.39
SIRT1 Q96EB6 1/20 0.39
SIRT3 Q9NTG7 1/20 0.39
CTDSP1 Q9GZU7 1/20 0.39
CYP3A4 P08684 1/20 0.38
TSHR P16473 1/20 0.38
PIN1 Q13526 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL10884537 0.98 ESRRA (0.54) ESRRASCN9AITGB2ICAM1ITGAL
SCHEMBL10963610 0.83 ESRRA (0.54) ESRRAITGB2ICAM1ITGALHPGD
SCHEMBL10359650 0.83 ALDH1A1 (0.44) ESRRAKDM1ARCOR1HPGDCYP1A2
SCHEMBL632218 0.83 CYP3A4 (0.46) HPGDRHEBCYP3A4TSHRALDH1A1
SCHEMBL11029673 0.82 ESRRA (0.47) ESRRASCN9AITGB2ICAM1ITGAL
SCHEMBL11029113 0.81 ESRRA (0.43) ESRRAHPGDCYP1A2CYP2A6HTR1B
SCHEMBL15084627 0.81 TRPA1 (0.48) ESRRASCN9AKDM1ARCOR1HPGD
SCHEMBL10961278 0.81 IDO1 (0.51) ESRRACYP3A4ALDH1A1GAA
SCHEMBL1964539 0.80 CYP3A4 (0.56) ITGB2ICAM1ITGALHPGDCYP3A4
SCHEMBL22069692 0.78 RHEB (0.45) HPGDRHEBCYP3A4TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004238-A1 FUSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-07 US disclosed
EP-2103620-A1 FUSED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-09-23 EP disclosed
WO-2005007083-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2005-01-27 WO disclosed
WO-2004112714-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-12-29 WO disclosed
EP-0081743-B1 NAPHTHOXYPHENYL UREAS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS HERBICIDES BASF Aktiengesellschaft (DE) 1986-05-14 EP disclosed
EP-0081743-A2 Naphthoxyphenyl ureas, process for their preparation and their use as herbicides BASF Aktiengesellschaft (DE) 1983-06-22 EP disclosed
EP-0013414-B1 UREA DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS INSECTICIDES CELAMERCK GmbH & Co. KG (DE) 1982-06-23 EP disclosed
EP-0050321-A2 Novel bicyclooxyphenyl ureas, process for their preparation and pesticides containing them UNION CARBIDE CORPORATION (US) 1982-04-28 EP disclosed
US-4275077-A Insecticidal acyl urea derivatives CELAMERCK GMBH & CO. KG (DE) 1981-06-23 US disclosed
EP-0013414-A2 Urea derivatives, process for their preparation and their use as insecticides CELAMERCK GmbH & Co. KG (DE) 1980-07-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004238-A1 FUSED HETEROCYCLIC COMPOUND ERBB2, ROS1, FLT3 ESRRA 1149/4885SCN9A 3444/4885ITGB2 2771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.